What does JP Garnier know that we don’t?

Trthman30 has just alerted me to interesting news about your friend and mine, JP Garnier the CEO of Glaxo. It seems his share options have been exercised and sold on straight away.

His actions are being discussed on investment sites around the world such as this one.

“I see from the news tab that Garnier has just exercised a goodly chunk of options and sold every last one of them, netting himself just under £6,000,000 in the process.

That doesn’t send a very encouraging signal to shareholders who would like to see these bigshots’ legs held firmly to the fire.

Makes you wonder what Garnier thinks about GSK?

Well, for sure, one thing he thinks is that, given an influx of almost 6 million ackers he’s got something better to do with the wonga than keep it in GSK shares!

I’m all for diversification, but it would have sent a better signal if he’d only trousered, say £5 million in cash and had held on to a tiny amount, say £700,000 worth of shares.

I do like to see these fat cats justify their stonking benefits by regularly jacking up their shareholdings, even if only slightly, rather than dumping the lot when option crystallising time arrives”.

Of course I’m sure his actions have nothing to do with the current Avandia crisis or the looming Seroxat litigation in the UK.

However, Avandia and Seroxat are not the only problems on JP’s desk. The company is also struggling in the face of a weak dollar, which has eroded the value of its sales across the US, the world’s largest pharmaceuticals market. Overall, the company is expected to report lower revenues and little change in earnings per share compared with last year.

Frustrated by the sluggish performance of its shares, Glaxo has already faced pressure from investors to consider a sale of its consumer healthcare unit, which includes the drinks brands Ribena and Lucozade, Aquafresh toothpaste and Nicorette antismoking patches.

In fact, the only way Glaxo could keep its share price up against all the bad news was to more than double its share buyback programme to £12 billion .

This boosted its shares even as sliding sales of diabetes drug Avandia held back second-quarter profit.

Garnier told reporters that the buyback would not affect Glaxo’s flexibility to do deals and the group had scope to borrow large amounts of money for the right acquisition…

“I’ll be a hero in three years” Jean-Pierre Garnier 5 April 2004

Posted in Glaxo. 2 Comments »

2 Responses to “What does JP Garnier know that we don’t?”

  1. truthman30 Says:

    It seems that GSK Investors are beginning to be just as cynical about GSK as have been the many patients who have been conned by GSK’s bogus drugs and marketing practices…

    http://www.iii.co.uk/investment/detail/?display=discussion&code=cotn%3AGSK.L&threshold=0&it=le&pageno=1

    “I am cynical
    crujack

    Most mergers seem to be for the benefit of the board members and b****r
    the shareholders. the merger between Glaxo and Smithkline was going to the best thing since sliced bread. it was—- for the board! Since then we have seen our shares go down, down, down.One excuse after another. When will this massive company start rewarding the shareholders or will pigs learn to fly first.”

    -And also you will notice that the GSK drug reps and salesmen have been voicing their disontent for a long time about working for GSK…

    -Words like “crooks” and “liars” are used often to describe GSK managers etc on the cafepharma GSK Board –

    http://www.cafepharma.com/boards/forumdisplay.php?f=26

  2. Seroxat - The Future « Fiddy’s Rants Says:

    […] We’d all love the ability to see into the future. With GlaxoSmithKline it’s pretty much easy to anticipate their next move. One only has to look at the history of this company and their stance on Seroxat. They have moved the goalposts that many times, cleverly releasing information relevant to their blunders on busy news days – only getting maybe 2 to 3 inches of space in the tabloids. From being a perfectly safe drug across the age spectrum, Seroxat users have been told over the years that, it is dangerous in people up to the age of 18… no wait… 24… no, hang on let GSK be more open… Here – dangerous for young adults. Quite a shift in attitude wouldn’t you agree? Of course Glaxo puppet, Alistair Benbow, still refutes that anything is wrong with Seroxat. I’m surprised he hasn’t been hauled over the coals by his bosses yet for some very outlandish quotes regarding the safety and efficacy of this particular medicine… then again his bosses are too busy sucking up to Jean-Paul Garnier, despite his lack of confidence in his own products. SELL! SELL! SELL! those shares Jeanie baby. […]


Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: